The availability of powerful genome-wide association study technology, during the last five years, has shown that most of the "new" MS susceptibility loci are immune-response genes.
It is clear that there is much novelty in the field of MS immunology, which has served as an impetus to invest in new therapies.
Notably, most if not all of these are immunotherapies.
Even the equally exciting field of cell-based therapies and neuro-regeneration may well rely on cells or growth factors that are no less immunomodulators than restorative of myelin and neural cell function. Multiple Sclerosis Immunology looks at MS immunology as the basis for the present and-even more-the future of treatments for this complex autoimmune condition.
Both editors are immunologists, as well as clinical neurologists, and appreciate the importance of a sustained dialogue between basic and clinical scientists to ensure that "translation" is real and not just virtual.